Proteinuria: abate or applaud abatacept in proteinuric kidney disease?

Jochen Reiser; Nada Alachkar

doi:10.1038/nrneph.2013.276

Proteinuria: abate or applaud abatacept in proteinuric kidney disease?

Research output: Contribution to journal › Review article › peer-review

Abstract

T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.

Original language	English (US)
Pages (from-to)	128-130
Number of pages	3
Journal	Nature Clinical Practice Nephrology
Volume	10
Issue number	3
DOIs	https://doi.org/10.1038/nrneph.2013.276
State	Published - Mar 2014
Externally published	Yes

ASJC Scopus subject areas

Nephrology

Access to Document

10.1038/nrneph.2013.276

Cite this

@article{4d5c6f66fbe84a708ab593b72f1f0565,

title = "Proteinuria: abate or applaud abatacept in proteinuric kidney disease?",

abstract = "T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.",

author = "Jochen Reiser and Nada Alachkar",

year = "2014",

month = mar,

doi = "10.1038/nrneph.2013.276",

language = "English (US)",

volume = "10",

pages = "128--130",

journal = "Nature Clinical Practice Nephrology",

issn = "1759-5061",

publisher = "Nature Publishing Group",

number = "3",

}

TY - JOUR

T1 - Proteinuria

T2 - abate or applaud abatacept in proteinuric kidney disease?

AU - Reiser, Jochen

AU - Alachkar, Nada

PY - 2014/3

Y1 - 2014/3

N2 - T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.

AB - T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.

UR - http://www.scopus.com/inward/record.url?scp=84906564596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906564596&partnerID=8YFLogxK

U2 - 10.1038/nrneph.2013.276

DO - 10.1038/nrneph.2013.276

M3 - Review article

C2 - 24375054

AN - SCOPUS:84906564596

SN - 1759-5061

VL - 10

SP - 128

EP - 130

JO - Nature Clinical Practice Nephrology

JF - Nature Clinical Practice Nephrology

IS - 3

ER -

Proteinuria: abate or applaud abatacept in proteinuric kidney disease?

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this